<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043870</url>
  </required_header>
  <id_info>
    <org_study_id>Combined therapy in CD</org_study_id>
    <nct_id>NCT05043870</nct_id>
  </id_info>
  <brief_title>Combined Immunosuppression for Pediatric Crohn's Disease</brief_title>
  <official_title>Combination Therapy of Infliximab and Immunosuppressives for Pediatric Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to compare the efficacy and safety of infliximab and&#xD;
      immunosuppressives therapy alone or in combination for pediatric Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical remission</measure>
    <time_frame>week 54</time_frame>
    <description>The clinical remission rate rate at week 54</description>
  </primary_outcome>
  <primary_outcome>
    <measure>endoscopic remission</measure>
    <time_frame>week 54</time_frame>
    <description>The endoscopic remission rate at week 54</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCDAI score</measure>
    <time_frame>week0, week2, week6, week14, week22, week30, week38, week46, week54</time_frame>
    <description>The Pediatric Crohn's disease Activity Index (PCDAI) was assessed at each infusion point (week0, week2, week6, week14, week22, week30, week38, week46, week54)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>infliximab concentration</measure>
    <time_frame>week 14, 38</time_frame>
    <description>The infliximab (IFX) concentration and anti-infliximab antibodies (ATI) were measured before the infusion of week 14, 38.</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>within one year</time_frame>
    <description>the potential adverse events were monitored during the intervention.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Infliximab</condition>
  <condition>Immunosuppression</condition>
  <condition>Children, Only</condition>
  <arm_group>
    <arm_group_label>infliximab and immunosuppressives therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1.5-2.5mg/kg per day or methotrexate 10-25 mg/m2 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infliximab therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab and immunosuppressives</intervention_name>
    <description>the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1.5-2.5mg/kg per day or methotrexate 10-25 mg/m2 week</description>
    <arm_group_label>infliximab and immunosuppressives therapy</arm_group_label>
    <other_name>IFX, IMMs, AZA, MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks</description>
    <arm_group_label>infliximab therapy</arm_group_label>
    <other_name>IFX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 2-18 years old&#xD;
&#xD;
          2. diagnosis of Crohn's Disease&#xD;
&#xD;
          3. receiving exclusive enteral nutrition or corticosteroids as first-line treatment,&#xD;
             Pediatric Crohn's disease Activity Index (PCDAI)&gt;10 or The Simple Endoscopic Score for&#xD;
             Crohn Disease (SES-CD)&lt;3 after exclusive enteral nutrition or corticosteroids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of biological agents targeting at tumor necrosis factor (TNF)&#xD;
&#xD;
          2. Crohn's Disease-related surgery&#xD;
&#xD;
          3. infections&#xD;
&#xD;
          4. tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Huang</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Wang</last_name>
    <phone>+8613817510412</phone>
    <email>wanglin546974055@163.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Ying HUANG</investigator_full_name>
    <investigator_title>Head of department of gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

